In a report released yesterday, Kostas Biliouris from BMO Capital maintained a Buy rating on Legend Biotech (LEGN – Research Report), ...

Legend Biotech (LEGN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Mitchell ...

Legend Biotech jumped Monday after the company said its J&J-tied multiple myeloma drug, Cavykti, cut the risk of death.

After putting on a strong performance in preventing disease progression in the earlier treatment of multiple myeloma, Johnson ...

Johnson & Johnson and Legend Biotech presented new data from the Phase 3 CARTITUDE-4 study, showing Carvykti significantly ...

Johnson & Johnson linked Carvykti to a 45% reduction in risk of death and Darzalex to a 61% improvement in minimal residual ...

Johnson & Johnson reported long-term Phase III CARTITUDE-4 study results showing that a single infusion of Carvykti ...

"Johnson & Johnson’s CARVYKTI improves survival in multiple myeloma trial" was originally created and published by Clinical ...

Johnson & Johnson and Legend Biotech's CAR-T cell therapy Carvykti reduced the risk of death by 45% compared to standard of ...

Binod Dhakal, MD, MS, discusses some of the challenges often seen in the myeloma space, particularly those with lenalidomide-refractory multiple myeloma.

The biotech expects that stopping enrollment for KarMMa-9, a trial evaluating early use of the multiple myeloma cell therapy Abecma, should save it $80 million in the near term.